245 related articles for article (PubMed ID: 29504483)
1. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).
Starling AJ; Tepper SJ; Marmura MJ; Shamim EA; Robbins MS; Hindiyeh N; Charles AC; Goadsby PJ; Lipton RB; Silberstein SD; Gelfand AA; Chiacchierini RP; Dodick DW
Cephalalgia; 2018 May; 38(6):1038-1048. PubMed ID: 29504483
[TBL] [Abstract][Full Text] [Related]
2. Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Open-Label Study.
Irwin SL; Qubty W; Allen IE; Patniyot I; Goadsby PJ; Gelfand AA
Headache; 2018 May; 58(5):724-731. PubMed ID: 29528485
[TBL] [Abstract][Full Text] [Related]
3. Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis.
Lloyd JO; Hill B; Murphy M; Al-Kaisy A; Andreou AP; Lambru G
J Headache Pain; 2022 Jun; 23(1):63. PubMed ID: 35668368
[TBL] [Abstract][Full Text] [Related]
4. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial.
Lipton RB; Dodick DW; Silberstein SD; Saper JR; Aurora SK; Pearlman SH; Fischell RE; Ruppel PL; Goadsby PJ
Lancet Neurol; 2010 Apr; 9(4):373-80. PubMed ID: 20206581
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
6. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
7. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.
Young W; Shaw J; Bloom M; Gebeline-Myers C
Headache; 2008; 48(10):1490-8. PubMed ID: 19076647
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
[TBL] [Abstract][Full Text] [Related]
10. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program.
Bhola R; Kinsella E; Giffin N; Lipscombe S; Ahmed F; Weatherall M; Goadsby PJ
J Headache Pain; 2015; 16():535. PubMed ID: 26055242
[TBL] [Abstract][Full Text] [Related]
11. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
12. Preventing Episodic Migraine With Caloric Vestibular Stimulation: A Randomized Controlled Trial.
Wilkinson D; Ade KK; Rogers LL; Attix DK; Kuchibhatla M; Slade MD; Smith LL; Poynter KP; Laskowitz DT; Freeman MC; Hoffer ME; Saper JR; Scott DL; Sakel M; Calhoun AH; Black RD
Headache; 2017 Jul; 57(7):1065-1087. PubMed ID: 28656612
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
17. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
18. Topiramate for migraine prevention in a naturalistic setting: results from an open label, flexible dose study.
Nelles G; Delbrück A; Schulze L; Kademann B; Bornhoevd K; Schäfer S; Schäuble B;
Headache; 2009; 49(10):1454-65. PubMed ID: 19804392
[TBL] [Abstract][Full Text] [Related]
19. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
20. Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.
Brandes JL; Smith T; Diamond M; Ames MH
Headache; 2007 Jun; 47(6):886-94. PubMed ID: 17578540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
